Abstract
Introduction
The treatment of psychiatric diseases is hardly straightforward; patients
often try many different drug regimens and combinations in order to identify
an optimal course of therapy. Although the long-term goal in treating
psychiatric diseases is to halt disease progression and to prevent the onset
of permanent damage, a more attainable step will be to individualize treatment
for patients using available drugs.
Get the Answers You Need to Shape Your Strategy
Psychiatric franchises are transforming as industry players concede potential
opportunities to others, capitalize on available opportunities, or challenge
others for coveted opportunities. What are the major psychiatric
franchises? What characteristics of the psychiatric industry make for a
dynamic market? Few innovative psychiatric drugs are in development;
however, psychiatric disease markets are substantial. Yet, big pharma' s
single-minded focus on developing the next blockbuster drug concedes a large
portion of pharmaceutical drug markets to midsize pharma companies. Which
midsize companies have the largest psychiatric franchises, and how are they fi
lling the market space conceded by big pharma? Identifying the genetic
variations associated with psychiatric diseases will be essential in the
development of drugs that provide personalized treatment options for patients.
What pharmacogenomics-based agents are currently in development?
Scope
- Psychiatric diseases: overview and prevalence of the major
psychiatric diseases in the seven major pharmaceutical markets (United States,
Europe France, Germany, Italy, Spain, and the United Kingdom, and
Japan).
- Worldwide psychiatric markets: a description of the psychiatric
pharmaceutical industry and the top-selling psychiatric drug brands of 2005.
- Major psychiatric franchises: dominant big pharma, midsize pharma,
and generics franchises.
- Psychiatric deals: a description of the recent license and
collaboration deals in the psychiatric industry.
- Outlook: the impact of industry dynamics on pharmaceutical
companies.
Mentioned in This Report-Companies
- Abbott Laboratories
- Affymetrix
- Albany Molecular Research
- Alza
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Carlsson Research
- Clinical Data
- Dr. Reddy' s Laboratories
- Eisai
- Eli Lilly
- Forest
- GlaxoSmithKline
- Ivax
- Johnson & Johnson
- Lundbeck
- Memory Pharmaceuticals
- Merck KGaA
- Mylan
- NeuroSearch
- Novartis
- Organon
- Otsuka
- Perlegen Sciences
- Pfi zer
- PGxHealth
- Reckitt Benckiser
- Sandoz
- Sanofi -Aventis
- Servier
- Shire Pharmaceuticals
- Solvay
- Targacept
- Teva Pharmaceuticals
- UCB
- Vanda Pharmaceuticals
- Verispan
- Vintage Pharmaceuticals
- Watson Pharmaceuticals
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Psychiatric Diseases
- Worldwide Psychiatric Markets-Top Brands
- Major Psychiatric Franchises
- Big Pharma Franchises
- AstraZeneca
- GlaxoSmithKline
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- Sanofi-Aventis
- Wyeth
- Midsize Pharma Franchises
- Generics Franchises
- Recent Psychiatric Deals
- Outlook
Figures
- 1. Total Prevalent Cases of Select Patient Populations, 2006
- 2. Blockbuster Psychiatric Drugs, 2005
- 3. Major Worldwide Psychiatric Franchises-Big and Midsize Pharma, 2005
- 4. Worldwide Generics Psychiatric Franchises, 2005
- 5. Genotype-Based Drug Doses for Antidepressants
Tables
- 1. Select Psychiatric Deals, 2005-2006
医薬品
その他のカテゴリ
FAQ